TechInSA & Austrade ‘HK–South China Market Desk’ | 18-22 June 2018
For the week of 18-22 June 2018 TechInSA will host a HK–South China Market Desk, staffed by Austrade Hong Kong’s Investment Manager, Catherine Dai.
The desk, based at TechInSA at Thebarton, will enable companies to have a Hong Kong and South China market advisory consultation in person. South Australia-based health and medtech companies are invited to meet with Ms Dai during her visit to Adelaide.
Ms Dai can advise companies on market development strategies for Hong Kong and the South China market, and talk through common pitfalls as well as key success factors to consider. With 12 years’ experience at Austrade, including nine as a Business Development Manager with Austrade in Beijing, Ms Dai has worked with many Australian exporters to enter Hong Kong and China in technology sectors including health, biotechnology, medical devices and diagnostics, aged care, smart cities, and creative technologies. Ms Dai has extensive experience in developing export and investment business opportunities, delivering focused inbound and outbound missions for Australian exporters, as well as working to maximise outcomes from ministerial visits.
Market opportunities in Hong Kong are attractive for competitive Australian health and medtech companies, and the Hong Kong Government has prioritised investment in innovation and technology as follows:
- A total of $50 billion has been earmarked for innovation development, focusing on healthcare, smart cities and artificial intelligence.
- The Hong Kong Government has committed to setting up a $1 billion fund to promote gerontology and subsidise elderly service units and NGOs to trial use and procure technology products.
- The Stock Exchange of Hong Kong Limited announced new rules to broaden Hong Kong’s listing regime, which now allows the listing of biotech companies that do not meet any of the financial eligibility tests of the main board, high-growth and innovative companies with weighted voting rights structures, and issuers seeking a secondary listing in Hong Kong. The new listing regime is expected to create more activity in the HK market from up-and-coming biotech companies, which make up a majority of pre-revenue companies seeking a listing.
Appointments with Catherine Dai are being coordinated by Austrade in Adelaide. To make an appointment, please email Lisa Brooks at Austrade’s Adelaide office on Lisa.Brooks@austrade.gov.au or call Lisa on 8202 7830.